All
All

What are you looking for?

All
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Strategies for the improvement of secondary metabolite production in plant cell culture of Panax species

Project goals

Panax ginseng C. A. Meyer (Araliaceae) is a herbal plant which is widely known as a tonicum, adaptogen and geriatricum. Saponins (called ginsenosides) are major pharmacological compounds however later studies showed an important biologic activity of somenon-saponin compounds. Cytotoxic activity in vitro has been documented for polyacetylenes isolated from ginseng roots. Ginseng polysaccharides have been reported to inhibit growth of tumour cells in vivo. The aim of the project is a study of ginsenosideproduction in in vivo cultures of Panax ginseng through testing the effect of different stress factors, elicitors or precursors. The accumulation of ginsenosides and polyacetylenes will be compared in different cell (callus and suspension cultures) andorgan cultures (adventitious roots, somatic embryos, in vitro regenerated plantlets). On the basis of acquired results we would optimize the process of ginsenoside production by selection of the most suitable growth and production cultivation medium and

Keywords

Public support

  • Provider

    Czech Science Foundation

  • Programme

    Post-graduate (doctorate) grants

  • Call for proposals

    Postdoktorandské granty 2 (SGA02002GA-PD)

  • Main participants

    Ústav organické chemie a biochemie AV ČR, v. v. i.

  • Contest type

    VS - Public tender

  • Contract ID

Alternative language

  • Project name in Czech

    Cesty ke zlepšení využitelnosti sekundárního metabolismu rostlin rodu Panax v in vitro kulturách

  • Annotation in Czech

    Panax ginseng C. A. Meyer (Araliaceae) je bylina, která je široce známá jako tonizující rostlina a jako adaptogen a geriatrikum. Hlavními farmakologickými účinnými látkami jsou saponiny (ginsenosidy), ale novější studie prokázaly významnou biologickouaktivitu i u některých nesaponinových sloučenin. U polyacetylenů izolovaných z ženšenu byla zjištěna cytotoxická aktivita in vitro a některé polysacharidy izolované z kořene ženšenu inhibují růst rakovinových buněk in vivo. V tomto projektu se budemezabývatprodukcí ginsenosidů a polyacetylenů v in vitro kulturách Panax ginseng. Chtěli bychom studovat vliv různých stresových faktorů, elicitorů či prekursorů a porovnat akumulaci ginsenosidů a polyacetylenů v různých buněčných (kalusové a suspenzní) aorgánových kulturách (např.: adventivní kořínky, somatická embrya, regenerované rostlinky). Na základě těchto výsledků bychom chtěli optimalizovat proces produkce sekundárních metabolitů ženšenu výběrem vhodného růstového a produkčního kultivačního média

Scientific branches

  • R&D category

    ZV - Basic research

  • CEP classification - main branch

    EI - Biotechnology and bionics

  • CEP - secondary branch

    EB - Genetics and molecular biology

  • CEP - another secondary branch

    CB - Analytical chemistry, separation

  • 10406 - Analytical chemistry
    10603 - Genetics and heredity (medical genetics to be 3)
    10604 - Reproductive biology (medical aspects to be 3)
    10605 - Developmental biology
    10608 - Biochemistry and molecular biology
    10609 - Biochemical research methods
    20801 - Environmental biotechnology
    20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
    20803 - Environmental biotechnology related ethics
    20901 - Industrial biotechnology
    20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
    20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
    30101 - Human genetics
    30401 - Health-related biotechnology
    30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
    30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
    30404 - Biomaterials (as related to medical implants, devices, sensors)
    30405 - Medical biotechnology related ethics
    40401 - Agricultural biotechnology and food biotechnology
    40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
    40403 - Agricultural biotechnology related ethics

Completed project evaluation

  • Provider evaluation

    V - Vynikající výsledky projektu (s mezinárodním významem atd.)

  • Project results evaluation

    Our results showed that differentiated tissue as adventitious roots of Panax ginseng C.A. Meyer is optimal for production of ginseng pharmacologically important compounds. Adventitious root cultures, contrary to callus cultures (undifferentiated tissue),

Solution timeline

  • Realization period - beginning

    Jan 1, 2002

  • Realization period - end

    Jan 1, 2004

  • Project status

    U - Finished project

  • Latest support payment

Data delivery to CEP

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

  • Data delivery code

    CEP/2005/GA0/GA05GP/U/N/A:8

  • Data delivery date

    Jul 23, 2008

Finance

  • Total approved costs

    759 thou. CZK

  • Public financial support

    663 thou. CZK

  • Other public sources

    96 thou. CZK

  • Non public and foreign sources

    0 thou. CZK

Basic information

Recognised costs

759 CZK thou.

Public support

663 CZK thou.

87%


Provider

Czech Science Foundation

CEP

EI - Biotechnology and bionics

Solution period

01. 01. 2002 - 01. 01. 2004